Celiac Panel: Normal Lab Ranges vs. Functional Optimal Levels

What a Celiac Panel Actually Measures

A celiac panel is a set of blood-based antibody tests used to screen for celiac disease, an autoimmune condition triggered by dietary gluten. The standard panel includes tissue transglutaminase IgA (tTG-IgA) as the primary marker, a total serum IgA level to rule out immunoglobulin deficiency, and in many labs, deamidated gliadin peptide (DGP) antibodies in both IgA and IgG classes.

The American College of Gastroenterology (ACG) 2023 updated guidelines recommend tTG-IgA as the single best serologic test for celiac disease detection in adults, with a pooled sensitivity of 93% and specificity of 96% [1]. Total serum IgA is ordered concurrently because selective IgA deficiency occurs in 2 to 3% of celiac patients compared to roughly 0.2% of the general population [2]. When IgA deficiency is present, the tTG-IgA result will be falsely low or negative regardless of disease activity. In those cases, DGP-IgG serves as the recommended alternative, with sensitivity around 94% in IgA-deficient individuals [3].

Endomysial antibodies (EMA-IgA) are sometimes included. EMA testing has near-perfect specificity (approaching 99%) but is more expensive and operator-dependent because it relies on immunofluorescence interpretation [1]. Most clinicians reserve EMA for confirmation when tTG-IgA results are equivocal.

Standard Reference Ranges and What They Miss

Most commercial laboratories report tTG-IgA as negative below 4 U/mL, weak positive between 4 and 10 U/mL, and positive above 10 U/mL. A result of 3.8 U/mL gets flagged as "normal." That single word can end a diagnostic workup prematurely.

The problem is that these cutoffs were established using cohorts with confirmed celiac disease (Marsh 3 villous atrophy) compared to healthy controls [4]. Patients with early mucosal changes (Marsh 1 or Marsh 2 lesions) often produce tTG-IgA values in the 4 to 10 U/mL range, and some generate values just below the negative threshold. A 2019 study published in Gut found that 17% of patients with biopsy-confirmed Marsh 1 intraepithelial lymphocytosis had tTG-IgA levels below standard positive cutoffs [5]. These patients had real intestinal inflammation. Their bloodwork said otherwise.

Dr. Alessio Fasano, Director of the Center for Celiac Research at Massachusetts General Hospital, has stated: "A negative serologic test does not exclude celiac disease, particularly in patients with selective IgA deficiency, those on a reduced-gluten diet, or those with early-stage mucosal lesions" [6].

The functional approach to interpreting celiac panels does not redefine "optimal" in the same way it might for vitamin D or thyroid markers. Celiac antibodies are autoimmune markers. The goal is absence, not a range. But the functional lens asks a different question: is a value of 3.5 U/mL in a patient with iron deficiency, brain fog, and bloating truly reassuring? Or does the clinical picture warrant further investigation despite a technically negative number?

The Gray Zone: Weak Positive and Borderline Negative Results

Values between 4 and 10 U/mL on tTG-IgA occupy a diagnostic gray zone where clinical context determines the next step. The ACG guidelines note that weak positive results should be confirmed with EMA-IgA or repeat testing before proceeding to biopsy [1]. A positive EMA in this setting has a predictive value exceeding 95% for villous atrophy.

Borderline negative values (2 to 4 U/mL) in symptomatic patients deserve a different framework than a clean negative in an asymptomatic person. Consider the following clinical layers:

Layer 1: Symptoms. Chronic diarrhea, iron-deficiency anemia unresponsive to oral iron, unexplained B12 deficiency, recurrent aphthous ulcers, or dermatitis herpetiformis all raise pre-test probability regardless of antibody level.

Layer 2: Associated conditions. Type 1 diabetes, autoimmune thyroid disease (Hashimoto's or Graves'), Down syndrome, Turner syndrome, and first-degree family history each increase celiac prevalence to 5 to 15% [7]. A 2015 screening study in Diabetes Care found celiac disease in 6.7% of adults with type 1 diabetes, a rate nearly seven times the general population [8].

Layer 3: Gluten exposure status. A patient who has already reduced gluten intake (even partially) may have suppressed antibodies. The ACG recommends consuming the equivalent of at least two slices of wheat-based bread daily for 6 to 8 weeks before serologic testing to avoid false negatives [1].

Layer 4: IgA sufficiency. If total serum IgA is below 7 mg/dL, every IgA-based celiac marker is unreliable. Switch to DGP-IgG and tTG-IgG [3].

When all four layers are assessed, many "normal" results reveal themselves as incomplete data points rather than clean bills of health.

Why 83% of Celiac Cases Stay Undiagnosed

Celiac disease affects approximately 1 in 100 people worldwide [6]. In the United States, a cross-sectional analysis using NHANES data estimated that 83% of Americans with celiac disease are undiagnosed or misdiagnosed [9]. The average time from symptom onset to diagnosis exceeds 6 years in U.S. adults, according to a survey by the Celiac Disease Foundation.

Several factors drive this diagnostic gap. Non-classical presentations now outnumber the "classic" triad of diarrhea, weight loss, and malabsorption. A 2021 meta-analysis in The Lancet Gastroenterology & Hepatology reported that 50 to 60% of newly diagnosed adults present with extraintestinal symptoms only: anemia, osteoporosis, elevated liver enzymes, peripheral neuropathy, or infertility [10]. Clinicians who only order celiac panels for patients with GI complaints will miss the majority.

The second driver is the threshold problem. Lab reports that display a simple "negative/positive" binary without context encourage pattern-matching rather than clinical reasoning. A tTG-IgA of 3.9 U/mL printed in normal-range formatting on a lab report does not prompt the same next step as the same value flagged with a note about clinical correlation in high-risk populations.

The Endocrine Society's 2012 clinical practice guideline on thyroid dysfunction screening in adults [11] established a precedent for thinking about autoimmune screening in overlapping conditions. Because autoimmune thyroiditis and celiac disease share HLA-DQ2/DQ8 haplotypes, the co-occurrence rate is 2 to 5% [7]. Patients already being evaluated for Hashimoto's thyroiditis may benefit from concurrent celiac screening even if GI symptoms are absent.

tTG-IgA Levels Above 10x the Upper Limit of Normal

Very high tTG-IgA values carry their own clinical significance. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 2020 guidelines allow a biopsy-free celiac diagnosis in children when tTG-IgA exceeds 10 times the upper limit of normal (ULN) and EMA-IgA is positive on a separate blood sample [12]. This threshold reflects the finding that tTG-IgA levels above 10x ULN have a positive predictive value of 99.75% for Marsh 3 villous atrophy [12].

In adults, the ACG has been more cautious. The 2023 guidelines still recommend duodenal biopsy as the confirmatory standard for adult patients [1]. However, a growing body of evidence suggests the pediatric approach may be applicable. A 2022 prospective study in Gastroenterology evaluated the ESPGHAN biopsy-free criteria in 436 adults and found a positive predictive value of 100% when tTG-IgA exceeded 10x ULN with confirmatory EMA positivity [13]. This may shift adult guidelines in coming years.

For patients with tTG-IgA in the 1 to 3x ULN range, biopsy remains necessary because the positive predictive value drops below 85% [1]. The interpretation should also account for concurrent conditions that can cause false-positive tTG-IgA elevations, including inflammatory bowel disease, chronic liver disease, congestive heart failure, and psoriasis [14].

How to Interpret DGP Antibodies

Deamidated gliadin peptide (DGP) tests measure antibodies against a modified form of gliadin, the immunogenic protein fraction in gluten. DGP-IgA has sensitivity of 88% and specificity of 95% for celiac disease. DGP-IgG reaches 94% sensitivity and 99% specificity [3].

DGP-IgG is the test of choice when IgA deficiency is confirmed. It also performs well in children under 2 years old, a population where tTG-IgA sensitivity drops because the immune response to tissue transglutaminase may not be fully developed [12].

A practical interpretation grid:

• tTG-IgA positive + DGP-IgA positive: Strong serologic evidence. Proceed to biopsy (adults) or consider biopsy-free diagnosis if tTG-IgA is above 10x ULN with positive EMA (pediatric/emerging adult criteria).
• tTG-IgA negative + DGP-IgG positive: Consider IgA deficiency, early disease, or non-celiac gluten sensitivity with cross-reactivity. Check total IgA.
• tTG-IgA weak positive + DGP negative: May represent a false positive tTG-IgA. Confirm with EMA before biopsy.
• All antibodies negative + high clinical suspicion: Verify gluten exposure was adequate. Consider HLA-DQ2/DQ8 genotyping (negative result effectively excludes celiac disease with >99% negative predictive value) [1].

HLA Genotyping: The Rule-Out Test

HLA-DQ2 and HLA-DQ8 genotyping does not diagnose celiac disease; roughly 30 to 40% of the general population carries one or both alleles [15]. Its value is exclusionary. The absence of both HLA-DQ2 and HLA-DQ8 makes celiac disease extremely unlikely, with a negative predictive value exceeding 99% [1].

This test is most useful in three scenarios. First, patients already on a gluten-free diet who never had serologic testing while eating gluten (HLA status is unaffected by diet). Second, first-degree relatives of confirmed celiac patients who want to know their genetic risk. Third, patients with equivocal serology and biopsy results where diagnostic certainty remains elusive.

The American Gastroenterological Association (AGA) position statement on celiac diagnosis notes that HLA genotyping should not be used as a first-line screening test because of its low positive predictive value in the general population [16]. Use it to rule out, not to rule in.

Monitoring Celiac Disease with Serial Antibody Levels

After diagnosis and initiation of a strict gluten-free diet (GFD), tTG-IgA levels should trend downward. The ACG recommends rechecking tTG-IgA at 6 and 12 months after starting the GFD [1]. Most patients will see a 50% or greater decline within 6 months, and the majority achieve seronegativity (tTG-IgA <4 U/mL) by 12 to 24 months [17].

Persistent elevation of tTG-IgA beyond 12 months on a GFD suggests ongoing gluten exposure (intentional or cross-contamination), an incorrect initial diagnosis, or the rare complication of refractory celiac disease. Refractory celiac disease type II carries a 5-year lymphoma risk of 60 to 80% and requires specialist management [18].

Dr. Peter Green, Director of the Celiac Disease Center at Columbia University, has noted: "Serologic monitoring is a useful surrogate for mucosal healing, but it is imperfect. About 30 to 40% of patients with normalized tTG-IgA still have persistent villous atrophy on follow-up biopsy" [17].

This disconnect means that a "normal" tTG-IgA after dietary treatment does not guarantee intestinal recovery. For patients with ongoing symptoms despite seronegativity, repeat duodenal biopsy may be warranted.

Iron, B12, and Thyroid: The Celiac Overlap Panel

Celiac disease damages the proximal small intestine, the primary absorption site for iron, folate, and fat-soluble vitamins. The distal ileum (B12 absorption site) can also be affected in extensive disease. A comprehensive evaluation alongside a celiac panel should include:

• Ferritin and iron studies: Iron-deficiency anemia is present in 30 to 50% of newly diagnosed celiac adults [19]. Unexplained iron deficiency that fails to respond to oral supplementation is one of the strongest indications for celiac screening according to the British Society of Gastroenterology [20].
• Vitamin B12 and folate: Deficiency prevalence ranges from 8 to 41% depending on disease extent [19].
• 25-hydroxyvitamin D: Low levels occur in up to 64% of untreated celiac patients, contributing to the elevated fracture risk seen in this population [21].
• TSH and TPO antibodies: Given the 2 to 5% co-occurrence of autoimmune thyroid disease, baseline thyroid screening is reasonable in all new celiac diagnoses [7]. The American Thyroid Association recommends screening for celiac disease in patients with autoimmune thyroid disease who present with GI symptoms or nutrient deficiencies [11].
• Bone density (DEXA scan): The AGA recommends baseline DEXA in adults with confirmed celiac disease because osteoporosis prevalence ranges from 28 to 38% at diagnosis [16].

These tests transform a celiac panel from an isolated antibody check into a functional assessment of disease impact. A patient whose tTG-IgA is 6 U/mL with a ferritin of 8 ng/mL, vitamin D of 14 ng/mL, and elevated TPO antibodies presents a very different clinical picture than the same tTG-IgA in isolation.

When to Retest and What to Expect

Retesting intervals depend on clinical context. For initial screening that returns negative results in a low-risk, asymptomatic patient, repeat testing is unnecessary. For high-risk individuals (first-degree relatives, type 1 diabetes, autoimmune thyroid disease), the ACG suggests periodic rescreening every 2 to 3 years or sooner if symptoms develop [1].

Post-diagnosis monitoring follows a tighter schedule: tTG-IgA at 6 months, 12 months, then annually. Persistent symptoms despite seronegativity should prompt evaluation for other causes (microscopic colitis, small intestinal bacterial overgrowth, lactose intolerance) or repeat biopsy.

One final point on timing: tTG-IgA has a half-life of approximately 6 weeks in circulation. A single negative test drawn 3 weeks after a patient stopped eating gluten is unreliable. The 6- to 8-week gluten challenge described in the ACG guidelines requires a minimum of 3 g of gluten daily (equivalent to about two slices of wheat bread) to be diagnostically valid [1].